Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(5):827-834; doi:10.1093/annonc/mdl033
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer
1 Fédération Francophone de Cancérologie Digestive (FFCD) and Equipe Mixte Inserm (EMI 106), Faculté de Médecine Dijon; 2 Centre Georges Francois Leclerc, DIM, Dijon; 3 Centre Hospitalier Universitaire Robert Debré, Reims; 4 Centre Hospitalier Universitaire Charles Nicolle, Rouen; 5 Centre Hospitalier Universitaire Claude Huriez, Lille; 6 Centre Alexis Vautrin, Nancy; 7 Centre Hospitalier Universitaire Hôtel Dieu, Clermond Ferrand; 8 Centre Hospitalier Universitaire Dupuytren, Limoges; 9 Institut Paoli-Calmettes, Marseille; 10 Centre Hospitalier Universitaire du Rouen, Rouen, France
* Correspondence to: Dr F. Bonnetain, Féderation Francophone de Cancérologie Digestive, Faculty of Medicine, 7 Boulevard Jeanne d'Arc, 21079 Dijon Cedex, France. Tel: +33-3-80-39-33-40; Fax: +33-3-80-66-82-51; E-mail: FBonnetain{at}dijon.fnclcc.fr
Background: The aim of the study was to compare the longitudinal quality of life (QoL) between chemoradiation with or without surgery in patients with locally advanced squamous resectable esophageal cancer included in a randomized multicenter phase III trial (FFCD 9102).
Materials and methods: All patients with locally advanced resectable (T3–4 N0–1 M0) epidermoid or glandular esophageal cancer (n = 451) received induction chemoradiation. Responders (n = 259) were randomized between surgery (arm A) and continuation of chemoradiation (arm B). The Spitzer QoL Index was scored (0–10) at inclusion and at each follow-up, every 3 months during 2 years. QoL at baseline and longitudinal changes were respectively compared with univariate ANOVA and mixed-model analysis of variance for repeated measurements. The time interval between the follow-up was assessed and the same analyses were performed among survivors with 2 years of follow-up.
Results: The squamous histology was predominant in both arms. The mean QoL score decreased between baseline and the first follow-up and between the first and the second follow-ups. QoL scores at the first follow-up were comparatively worse in arm A than in arm B (7.52 versus 8.45, P < 0.01), whereas the longitudinal QoL study showed no difference between treatments (adjusted P = 0.26). Furthermore, the longitudinal QoL was not different (adjusted P = 0.23) among survivors with 2 years of follow-up.
Conclusions: Among patients responding to induction chemoradiation, surgery and continuation of chemoradiation had the same impact on QoL in patients with locally advanced, resectable esophageal cancer although a significantly greater decrease in the Spitzer Index was observed in the postoperative period.
Key words: quality of life, esophageal cancer, clinical trials, longitudinal, surgery, radio-chemotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Safieddine, W. Xu, S. M. Quadri, J. J. Knox, J. Hornby, J. Sulman, R. Wong, M. Guindi, S. Keshavjee, and G. Darling Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J. Thorac. Cardiovasc. Surg., January 1, 2009; 137(1): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-B. D'Journo, P. Michelet, L. Dahan, C. Doddoli, J.-F. Seitz, R. Giudicelli, P. A. Fuentes, and P. A. Thomas Indications and outcome of salvage surgery for oesophageal cancer Eur. J. Cardiothorac. Surg., June 1, 2008; 33(6): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Crehange, P. Maingon, K. Peignaux, T. D. N'guyen, X. Mirabel, C. Marchal, P. Verrelle, B. Roullet, F. Bonnetain, and L. Bedenne Phase III Trial of Protracted Compared With Split-Course Chemoradiation for Esophageal Carcinoma: Federation Francophone de Cancerologie Digestive 9102 J. Clin. Oncol., November 1, 2007; 25(31): 4895 - 4901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gotoh, H. Takiuchi, S.-i. Kawabe, S. Ohta, T. Kii, S. Kuwakado, and K.-i. Katsu Epidermal Growth Factor Receptor is a Possible Predictor of Sensitivity to Chemoradiotherapy in the Primary Lesion of Esophageal Squamous Cell Carcinoma Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 652 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kii, H. Takiuchi, S. Kawabe, M. Gotoh, S. Ohta, T. Tanaka, S. Kuwakado, H. Nishitani, and K.-i. Katsu Evaluation of Prognostic Factors of Esophageal Squamous Cell Carcinoma (Stage II III) After Concurrent Chemoradiotherapy Using Biopsy Specimens Jpn. J. Clin. Oncol., August 20, 2007; (2007) hym077v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Kang, J. H. Han, K. J. Lee, J.-H. Choi, J. I. Park, H. I. Kim, H.-W. Lee, J. H. Jang, J. S. Park, H. C. Kim, et al. Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy Clin. Cancer Res., July 15, 2007; 13(14): 4146 - 4153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-C Lin, C-H Hsu, J. Cheng, H-P Wang, J-M Lee, K-H Yeh, C-H Yang, J-T Lin, A-L Cheng, and Y-C Lee Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer Ann. Onc., January 1, 2007; 18(1): 93 - 98. [Abstract] [Full Text] [PDF]
|
|